RESUMEN
The Elekta Unity magnetic resonance (MR) linac is limited to longitudinal couch motion and a sagittal-only laser, which restricts the ability to perform patient-specific quality assurance (PSQA) intensity-modulated radiotherapy (IMRT) measurements for very lateral targets. This work introduces a simple method to perform PSQA using the Sun Nuclear ArcCheck-MR phantom at left and right lateral positions without additional equipment or in-house construction. The proposed setup places the center of the phantom 1.3 cm vertical and 12.9 cm lateral to isocenter in either the left or right direction. Computed tomography (CT) scans are used to simulate the setup and create a QA plan template in the Monaco treatment planning system (TPS). The workflow is demonstrated for four patients, with an average axial distance from the center of the bore to the planning target volume (PTV) of 12.4 cm. Gamma pass rates were above 94% for all plans using global 3%/2 mm gamma criterion with a 10% threshold. Setup uncertainties are slightly larger for the proposed lateral setup compared to the centered setup on the Elekta platform (â¼1 mm compared to â¼0.5 mm), but acceptable pass rates are achievable without optimizing shifts in the gamma analysis software. In general, adding the left and right lateral positions increases the axial area in the bore encompassed by the cylindrical measurement array by 147%, substantially increasing the flexibility of measurements for offset targets. Based on this work, we propose using the lateral QA setup if the closest distance to the PTV edge from isocenter is larger than the array radius (10.5 cm) or the percent of the PTV encompassed by the diode array would be increased with the lateral setup compared to the centered setup.
Asunto(s)
Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada , Humanos , Planificación de la Radioterapia Asistida por Computador/métodos , Imagen por Resonancia Magnética , Aceleradores de Partículas , Radioterapia de Intensidad Modulada/métodos , Espectroscopía de Resonancia Magnética , Dosificación RadioterapéuticaRESUMEN
Create a virtual ArcCHECK-MR phantom, customized for a 1.5T MR-linac, with consideration of the different density regions within the quality assurance (QA) phantom, aiming to streamline the utilization of this specialized QA device. A virtual phantom was constructed in the treatment planning system (TPS) to replicate the ArcCHECK-MR's composition, consisting of five distinct layers: "Outer" (representing the outer PMMA ring), "Complex" (simulating the printed circuit boards), "Detectors" (encompassing the detector area), "Inner" (signifying the inner PMMA ring) and "Insert" (representing the PMMA insert). These layers were defined based on geometric data and represented as contour points on a set of dummy CT images. Additionally, a setup platform was integrated as contoured structures. To determine the relative electron density (RED) values of the external and internal PMMA components, measurements were taken at 25 points in the insert using an ion chamber. A novel method for establishing the exit/entrance dose ratio (EEDR) for ArcCHECK-MR was introduced. The RED of higher density region was derived by evaluating the local gamma index passing rate results with criteria of 2% dose difference and 2 mm distance-to-agreement. The performance of the virtual phantom was assessed for Unity 7 FFF beams with a 1.5T magnetic field. The radii of the five ring structures within the virtual phantom measured 133.0 mm, 110.0 mm, 103.4 mm, 100.0 mm, and 75.0 mm for the "Outer," "Complex," "Detectors," "Inner" and "Insert" regions, respectively. The RED values were as follows: ArcCHECK-MR PMMA had a RED of 1.130, "Detectors" were assumed to have a RED of 1.000, "Complex" had a RED of 1.200, and the setup QA phantom justified a RED of 1.350. Early validation results demonstrate that the 5-layer virtual phantom, when compared to the commonly used bulk overridden phantom, offers improved capability in MR-linac environments. This enhancement led to an increase in passing rates for the local gamma index by approximately 5 â¼ 6%, when applying the criteria of 2%, 2 mm. We have successfully generated a virtual representation of the distinct regions within the ArcCHECK-MR using a TPS, addressing the challenges associated with its use in conjunction with a 1.5T MR-linac. We consistently observed favorable local gamma index passing rates across two 1.5T MR-linac and ArcCHECK-MR unit combinations. This approach has the potential to minimize uncertainties in the creation of the QA phantom for ArcCHECK-MR across various institutions.
Asunto(s)
Imagen por Resonancia Magnética , Aceleradores de Partículas , Fantasmas de Imagen , Garantía de la Calidad de Atención de Salud , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por Computador , Humanos , Garantía de la Calidad de Atención de Salud/normas , Planificación de la Radioterapia Asistida por Computador/métodos , Aceleradores de Partículas/instrumentación , Imagen por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/normas , Radioterapia de Intensidad Modulada/métodos , Neoplasias/radioterapia , Neoplasias/diagnóstico por imagenRESUMEN
PURPOSE: Single-isocenter multi-target intracranial stereotactic radiotherapy (SIMT) is an effective treatment for brain metastases with complex treatment plans and delivery optimization necessitating rigorous quality assurance. This work aims to assess five methods for quality assurance of SIMT treatment plans in terms of their suitability and sensitivity to delivery errors. METHODS: Sun Nuclear ArcCHECK and SRS MapCHECK, GafChromic EBT Radiochromic Film, machine log files, and Varian Portal Dosimetry were all used to measure 15 variations of a single SIMT plan. Variations of the original plan were created with Python. They comprised various degrees of systematic MLC offsets per leaf up to 2 mm, random per-leaf variations with differing minimum and maximum magnitudes, simulated collimator, and dose miscalibrations (MU scaling). The erroneous plans were re-imported into Eclipse and plan-quality degradation was assessed by comparing each plan variation to the original clinical plan in terms of the percentage of clinical goals passing relative to the original plan. Each erroneous plan could be then ranked by the plan-quality degradation percentage following recalculation in the TPS so that the effects of each variation could be correlated with γ pass rates and detector suitability. RESULTS & CONCLUSIONS: It was found that 2%/1 mm is a good starting point for the ArcCHECK, Portal Dosimetry, and the SRS MapCHECK methods, respectively, and provides clinically relevant error detection sensitivity. Looser dose criteria of 5%/1 mm or 5%/1.5 mm are suitable for film dosimetry and log-file-based methods. The statistical methods explored can be expanded to other areas of patient-specific QA and detector assessment.
Asunto(s)
Neoplasias Encefálicas , Garantía de la Calidad de Atención de Salud , Radiocirugia , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada , Humanos , Planificación de la Radioterapia Asistida por Computador/métodos , Neoplasias Encefálicas/radioterapia , Radiocirugia/métodos , Radiocirugia/instrumentación , Garantía de la Calidad de Atención de Salud/normas , Radioterapia de Intensidad Modulada/métodos , Aceleradores de Partículas/instrumentación , Radiometría/métodos , Radiometría/instrumentación , AlgoritmosRESUMEN
PURPOSE: To evaluate the impact of the Acuros XB spatial discretization errors on ArcCHECK volumetric modulated arc therapy (VMAT) QA for small-field SBRT plans. METHODS: Eighteen SBRT VMAT arcs that failed the ArcCHECK VMAT QA were retrospectively analyzed. Plan verification doses were calculated using Eclipse Acuros XB, and absolute 3%/2 mm gamma passing rates were calculated to compare ArcCHECK and MapCHECK2 with MapPHAN. Verification doses were recalculated using AAA in Eclipse and with the EGSnrc Monte Carlo package. In addition, error-reduced Acuros XB doses were calculated by subdividing the entire arc into several sub-arcs ("split-arc" method), with the angular ranges of the sub-arcs optimized to balance accuracy and efficiency. Relative gamma passing rates were calculated and compared for the four methods: (1) Acuros XB; (2) AAA; (3) EGSnrc Monte Carlo; and (4) the split-arc method. RESULTS: The absolute gamma passing rates were below 90% for ArcCHECK and above 95% for MapCHECK2. The averaged relative gamma passing rates were (1) 84.7% for clinical Acuros XB; (2) 96.8% for AAA; (3) 98.8% for EGSnrc Monte Carlo; and (4) 96.8% for the split-arc method with 60° sub-arc angle. Compared to the clinical Acuros XB, the split-arc method improved the relative gamma passing rate by 12.1% on average. No significant difference was found between AAA and the split-arc method (p > 0.05). CONCLUSION: The Acuros XB spatial discretization errors can significantly impact the ArcCHECK VMAT QA results for small-field SBRT plans. The split-arc method may be used to improve the VMAT QA results.
Asunto(s)
Radiocirugia , Radioterapia de Intensidad Modulada , Humanos , Radioterapia de Intensidad Modulada/métodos , Estudios Retrospectivos , Planificación de la Radioterapia Asistida por Computador/métodos , Fantasmas de Imagen , Dosificación RadioterapéuticaRESUMEN
PURPOSE: A signal dependence on dose rate was reported for the ArcCHECK array due to recombination processes within the diodes. The purpose of our work was to quantify the necessary correction and apply them to quality assurance measurements. METHODS: Static 10 × 10 cm2 6-MV fields delivered by a linear accelerator were applied to the detector array while decreasing the average dose rate, that is, the pulse frequency, from 500 to 30 MU/min. An ion chamber was placed inside the ArcCHECK cavity as a reference. Furthermore, the instantaneous dose rate dependence (DRD) was studied. The position of the detector was adjusted to change the dose-per-pulse, varying the distance between the focus and the diode closest to the focus between 69.6 and 359.6 cm. Reference measurements were performed with an ion chamber placed inside a PMMA slab phantom at the same source-to-detector distances ( S D D s ) . Exponential saturation functions were fitted to the data, with different parameters to account for two generations of ArcCHECK detectors (types 2 and 3) and both DRDs. Corrections were applied to 12 volumetric modulated arc therapy plans. RESULTS: The sensitivity decreased by up to 2.8% with a decrease in average dose rate and by 9% with a decrease in instantaneous dose rate. Correcting the average DRD, the mean gamma pass rates (2%/2-mm criterion) of the treatment plans were improved by 5 percentage points (PP) for diode type 3 and 0.4 PP for type 2. Correcting the instantaneous DRD, the improvement was 8.4 PP for type 3 and 0.9 PP for type 2. CONCLUSIONS: The instantaneous DRD was identified as the prevailing effect on the diode sensitivity. We developed and validated a method to correct this behavior. The number of falsely not passed treatment plans could be considerably reduced.
Asunto(s)
Radioterapia de Intensidad Modulada , Silicio , Humanos , Aceleradores de Partículas , Garantía de la Calidad de Atención de Salud , Radiometría , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
Institutions use a range of different detector systems for patient-specific quality assurance (QA) measurements conducted to assure that the dose delivered by a patient's radiotherapy treatment plan matches the calculated dose distribution. However, the ability of different detectors to detect errors from different sources is often unreported. This study contains a systematic evaluation of Sun Nuclear's ArcCHECK in terms of the detectability of potential machine-related treatment errors. The five investigated sources of error were multileaf collimator (MLC) leaf positions, gantry angle, collimator angle, jaw positions, and dose output. The study encompassed the clinical treatment plans of 29 brain cancer patients who received stereotactic ablative radiotherapy (SABR). Six error magnitudes were investigated per source of error. In addition, the Eclipse AAA beam model dosimetric leaf gap (DLG) parameter was varied with four error magnitudes. Error detectability was determined based on the area under the receiver operating characteristic (ROC) curve (AUC). Detectability of DLG errors was good or excellent (AUC >0.8) at an error magnitude of at least ±0.4 mm, while MLC leaf position and gantry angle errors reached good or excellent detectability at error magnitudes of at least 1.0 mm and 0.6°, respectively. Ideal thresholds, that is, gamma passing rates, to maximize sensitivity and specificity ranged from 79.1% to 98.7%. The detectability of collimator angle, jaw position, and dose output errors was poor for all investigated error magnitudes, with an AUC between 0.5 and 0.6. The ArcCHECK device's ability to detect errors from treatment machine-related sources was evaluated, and ideal gamma passing rate thresholds were determined for each source of error. The ArcCHECK was able to detect errors in DLG value, MLC leaf positions, and gantry angle. The ArcCHECK was unable to detect the studied errors in collimator angle, jaw positions, and dose output.
Asunto(s)
Radioterapia de Intensidad Modulada , Encéfalo , Humanos , Garantía de la Calidad de Atención de Salud , Curva ROC , Radiometría , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
PURPOSE: To investigate intrinsic sensitivity of an electronic portal imaging device (EPID) and the ArcCHECK detector and to use this in assessing their performance in detecting delivery variations for lung SBRT VMAT. The effect of detector spatial resolution and dose matrix interpolation on the gamma pass rate was also considered. MATERIALS AND METHODS: Fifteen patients' lung SBRT VMAT plans were used. Delivery variations (errors) were introduced by modifying collimator angles, multi-leaf collimator (MLC) field sizes and MLC field shifts by ±5, ±2, and ±1 degrees or mm (investigating 103 plans in total). EPID and ArcCHECK measured signals with introduced variations were compared to measured signals without variations (baseline), using OmniPro-I'mRT software and gamma criteria of 3%/3 mm, 2%/2 mm, 2%/1 mm, and 1%/1 mm, to test each system's basic performance. The measurement sampling resolution for each was also changed to 1 mm and results compared to those with the default detector system resolution. RESULTS: Intrinsic detector sensitivity analysis, that is, comparing measurement to baseline measurement, rather than measurement to plan, demonstrated the intrinsic constraints of each detector and indicated the limiting performance that users might expect. Changes in the gamma pass rates for ArcCHECK, for a given introduced error, were affected only by dose difference (DD %) criteria. However, the EPID showed only slight changes when changing DD%, but greater effects when changing distance-to-agreement criteria. This is pertinent for lung SBRT where the minimum dose to the target will drop dramatically with geometric errors. Detector resolution and dose matrix interpolation have an impact on the gamma results for these SBRT plans and can lead to false positives or negatives in error detection if not understood. CONCLUSION: The intrinsic sensitivity approach may help in the selection of more meaningful gamma criteria and the choice of optimal QA device for site-specific dose verification.
Asunto(s)
Radiocirugia , Radioterapia de Intensidad Modulada , Humanos , Pulmón , Garantía de la Calidad de Atención de Salud , Radiometría , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
OBJECTIVES: To study the feasibility of ArcCHECK-3DVH system in dosimetric verification for stereotactic body radiaotherapy (SBRT) with flattening filter free (FFF) model. METHODS: SBRT treatment plans for 57 patients were introduced into ArcCHECK phantom and recalculated. The calculated dose distribution of treatment planning system and the measured dose distribution of ArcCHECK phantom were compared by γ analysis. Then the 3 dimensional dose distribution of target and organs at risk was reconstructed by 3DVH software. The reconstructed dose and calculated dose with treatment planning system (TPS) were compared, and the dose volume γ pass rate and deviation of dose volume parameters to the target and organs at risk were quantitatively valuated. RESULTS: Based on the threshold criteria (3%, 3 mm, 10%), namely the deviation of measuring points between the planned value and the measured value was less than 3%, and the proportion of points with similar values in the plane or sphere with the center of the point and the radius of 3 mm was 10%, the relative and absolute dose pass rates of SBRT treatment plans in ArcCHECK system via γ analysis were greater than 95%. Based on the stricter threshold criteria (2%, 2 mm, 10%), the relative and absolute dose pass rates of SBRT treatment plan in ArcCHECK system via γ analysis were about 93%. In 3DVH dose verification, the γ pass rate of target and organs at risk was exceed 97%, and the deviations in 3DVH of the target and organs at risk were less than ±5%. CONCLUSIONS: The ArcCHECK-3DVH system in dose verification can provide more comprehensive dose distribution information to reasonably evaluate the SBRT plan, with more significance for guiding clinical treatment.
Asunto(s)
Radiocirugia , Radioterapia de Intensidad Modulada , Humanos , Fantasmas de Imagen , Garantía de la Calidad de Atención de Salud , Radiometría , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
AIM OF THE STUDY: To evaluate the agreement between planned and delivered doses and its potential correlation with the plans' complexity subjected to dosimetric verification. MATERIAL AND METHODS: Four isocentre volumetric modulated arc therapy for total marrow irradiation plans optimized simultaneously with (P1) and without (P2) MU reduction were evaluated dosimetrically by γ method performed in a global mode for 4 combinations of γ-index criteria (2%/2 mm, 2%/3 mm, 3%/2 mm, and 3%/3 mm). The evaluation was conducted for 4 regions (head and neck, chest, abdomen and upper pelvis, and lower pelvis and thighs) that were determined geometrically by the isocentres. The Wilcoxon test was used to detect significant differences between γ passing rate (GPR) analysis results for the P1 and P2 plans. The Pearson correlation was used to check the relationship between GPR and the plans' complexity. RESULTS: Except for the head and neck region, the P2 plans had better GPRs than the P1 plans. Only for hard combinations of γ-index criteria (i.e. 2%/3 mm, 2%/2 mm) were the GPRs differences between P1 and P2 clinically meaningful, and they were detected in the chest, abdomen and upper pelvis, and lower pelvis and thighs regions. The highest correlations between GPR and the indices describing the plans' complexity were found for the chest region. No correlation was found for the head and neck region. CONCLUSIONS: The P2 plans showed better agreement between planned and delivered doses compared to the P1 plans. The GPR and the plans' complexity depend on the anatomy region and are most important for the chest region.
RESUMEN
PURPOSE: Integrating log file analysis with LINACWatch® (LW) into clinical routine as part of the quality assurance (QA) process could be a time-saving strategy that does not compromise on quality. The purpose is to determine the error sensitivity of log file analysis using LINACWatch® compared with a measurement device (ArcCHECK®, AC) for VMAT delivery QA. MATERIALS AND METHODS: Multi-leaf collimator (MLC) errors, collimator angle errors, MLC shift errors and dose errors were inserted to analyze error detection sensitivity. A total of 36 plans were manipulated with different magnitudes of errors. The gamma index protocols for AC were 3%/3 mm/Global and 2%/2 mm/Global, as well as 2%/2 mm/Global, and 1.5%/1.5 mm/Global for LW. Additionally, deviations of the collimator and monitor units between TPS and log file were calculated as RMS values. A 0.125 cm3 ionization chamber was used to independently examine the effect on dose. RESULTS: The sensitivity for AC was 20.4% and 49.6% vs 63.0% and 86.5% for LW, depending on the analysis protocol. For MLC opening and closing errors, the detection rate was 19.0% and 47.7% for AC vs 50.5% and 75.5% for LW. For MLC shift errors, it was 29.6% and 66.7% for AC vs 66.7% and 83.3% for LW. AC could detect 25.0% and 44.4% of all collimator errors. Log file analysis detected all collimator errors using 1° detection level. 13.2% and 42.4% of all dose errors were detected by AC vs 59.0% and 92.4% for LW using gamma analysis. Using RMS value, all dose errors were detected by LW (1% detection level). CONCLUSION: The results of this study clearly show that log file analysis is an excellent complement to phantom-based delivery QA of VMAT plans. We recommend a 1.5%/1.5 mm/Global criteria for log file-based gamma calculations. Log file analysis was implemented successfully in our clinical routine for VMAT delivery QA.
Asunto(s)
Dosímetros de Radiación , Radioterapia de Intensidad Modulada , Humanos , Fantasmas de Imagen , Garantía de la Calidad de Atención de Salud , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
The aim of current work was to present a novel evaluation procedure implemented for checking the constancy of beam path accuracy of a CyberKnife system based on ArcCHECK. A tailor-made Styrofoam with four implanted fiducial markers was adopted to enable the fiducial tracking during beam deliveries. A simple two-field plan and an isocentric plan were created for determining the density override of ArcCHECK in MultiPlan and the constancy of beam path accuracy respectively. Correlation curves for all diodes involved in the study were obtained by analyzing the dose distributions calculated by MultiPlan after introducing position shifts in anteroposterior, superoinferior, and left-right directions. The ability of detecting systematic position error was also evaluated by changing the position of alignment center intentionally. The one standard deviation (SD) result for reproducibility test showed the RMS of 0.054 mm and the maximum of 0.263 mm, which was comparable to the machine self-test result. The mean of absolute value of position errors in the constancy test was measured to 0.091 mm with a SD of 0.035 mm, while the root-mean-square was 0.127 mm with a SD of 0.034 mm. All introduced systematic position errors range from 0.3 to 2 mm were detected successfully. Efficient method for evaluating the constancy of beam path accuracy of CyberKnife has been developed and proven to be sensitive enough for detecting a systematic drift of robotic manipulator. Once the workflow is streamlined, our proposed method will be an effective and easy quality assurance procedure for medical physicists.
Asunto(s)
Marcadores Fiduciales , Neoplasias/cirugía , Fantasmas de Imagen , Garantía de la Calidad de Atención de Salud/normas , Radiocirugia/instrumentación , Planificación de la Radioterapia Asistida por Computador/métodos , Algoritmos , Humanos , Modelos Estadísticos , Control de Calidad , Radiocirugia/métodos , Dosificación Radioterapéutica , Radioterapia de Intensidad Modulada/métodos , Reproducibilidad de los ResultadosRESUMEN
PURPOSE: Intensity modulated radiation therapy (IMRT) has become a widely accepted and efficient treatment technique for many types of cancers. Patient's specific quality assurance (QA) should be performed with QA devices. Stability and sensitivity tests conducted on the ArcCHECK (AC) 3D diode array were performed. METHODS: Set-up error test with AC was performed. The set-up position moved to lateral (mm), longitudinal (mm) and rotational (°) were 0.5, 1.0, 2.0 and 3.0, respectively. Sensitivity change test of diode array with AC through 230 days was also performed. Same array calibration data was applied to all measurements of volumetric-modulated arc therapy benchmark test through 230 days. Gamma method (2 mm/2% criteria) was performed to analyze the result of all measurements. RESULTS: In the results of positional error, gamma pass rate become degenerate according to positional error became larger. With 0.5 mm or 0.5° positional error, decreasing rate of the pass rate of lateral, longitudinal and rotational were 1.0%, 2.5% and 4.2%, respectively. In the sensitivity change test, the gamma pass rate decreased 2.2%/100 days with same calibration data. CONCLUSION: AC has highly sensitivity against positional error. Sensitivity of AC has been changed and pass rate was decreased 2.2%/100 days through 230 days. Array calibration should be performed in consideration of change of sensitivity.
Asunto(s)
Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada , Calibración , Humanos , Garantía de la Calidad de Atención de Salud , Radiometría , Dosificación RadioterapéuticaRESUMEN
PURPOSE: To assess the efficiency of combined use of ArcCheck® detector (AC) and portal dosimetry (PDIP) for delivery quality assurance of head and neck and prostate volumetric-modulated arc therapy. MATERIALS AND METHODS: Measurement processes were studied with the Gamma index method according to three analysis protocols. The detection sensitivity to technical errors of each individual or combined measurement processes was studied by inserting collimator, dose and MLC opening error into five head and neck and five prostate initial treatment plans. A total of 220 plans were created and 660 analyses were conducted by comparing measurements to error free planned dose matrix. RESULTS: For head and neck localization, collimator errors could be detected from 2° for AC and 3° for PDIP. Dose and MLC errors could be detected from 2% and 0.5 mm for AC and PDIP. Depending on the analysis protocol, the detection sensitivity of total simulated errors ranged from 54% to 88% for AC vs 40% to 74% for PDIP and 58% to 92% for the combined process. For the prostate localization, collimator errors could be detected from 4° for AC while they could not be detected by PDIP. Dose and MLC errors could be detected from 3% and 0.5 mm for AC and PDIP. The detection sensitivity of total simulated errors ranged from 30% to 56% for AC vs 16% to 38% for PDIP and 30% to 58% for combined process. CONCLUSION: The combined use of the two measurement processes did not statistically improve the detectability of technical errors compared to use of single process.
Asunto(s)
Neoplasias de Cabeza y Cuello/radioterapia , Neoplasias de la Próstata/radioterapia , Garantía de la Calidad de Atención de Salud/normas , Radiometría/normas , Planificación de la Radioterapia Asistida por Computador/métodos , Radioterapia de Intensidad Modulada/normas , Humanos , Masculino , Pronóstico , Radiometría/instrumentación , Radiometría/métodos , Dosificación Radioterapéutica , Radioterapia de Intensidad Modulada/instrumentaciónRESUMEN
A volumetric modulated arc therapy (VMAT) approach to total body irradiation (TBI) has recently been introduced at our institution. The planning target volume (PTV) is divided into separate sub-volumes, each being treated with 2 arcs with their own isocentre. Pre-treatment quality assurance of beams is performed on a Sun Nuclear ArcCHECK diode array. Measurement of junction regions between VMAT arcs with separate isocentres has previously been performed with point dose ionization chamber measurements, or with films. Translations of the ArcCHECK with respect to a known distance between the adjacent isocentres of two arcs, which are repeated with the ArcCHECK in an inverted position, allows the recording of a junction dose map. A 3%/3 mm global gamma analysis (10% threshold) pass rate for arc junctions were comparable to their component arcs. Dose maps of junction regions between adjacent arcs with different isocentres can be readily measured on a Sun Nuclear ArcCHECK diode array.
Asunto(s)
Fantasmas de Imagen , Radiometría/instrumentación , Radiometría/normas , Planificación de la Radioterapia Asistida por Computador/métodos , Planificación de la Radioterapia Asistida por Computador/normas , Radioterapia de Intensidad Modulada/normas , Irradiación Corporal Total , Humanos , Garantía de la Calidad de Atención de Salud , Radiometría/métodos , Dosificación Radioterapéutica , Radioterapia de Intensidad Modulada/instrumentación , Radioterapia de Intensidad Modulada/métodos , Reproducibilidad de los ResultadosRESUMEN
The ArcCHECK-MR diode array utilizes a correction system with a virtual inclinometer to correct the angular response dependencies of the diodes. However, this correction system cannot be applied to measurements on the ViewRay MR-IGRT system due to the virtual inclinometer's incompatibility with the ViewRay's multiple simultaneous beams. Additionally, the ArcCHECK's current correction factors were determined without magnetic field effects taken into account. In the course of performing ViewRay IMRT quality assurance with the ArcCHECK, measurements were observed to be consistently higher than the ViewRay TPS predictions. The goals of this study were to quantify the observed discrepancies and test whether applying the current factors improves the ArcCHECK's accuracy for measurements on the ViewRay. Gamma and frequency analysis were performed on 19 ViewRay patient plans. Ion chamber measurements were performed at a subset of diode locations using a PMMA phantom with the same dimensions as the ArcCHECK. A new method for applying directionally dependent factors utilizing beam information from the ViewRay TPS was developed in order to analyze the current ArcCHECK correction factors. To test the current factors, nine ViewRay plans were altered to be delivered with only a single simultaneous beam and were measured with the ArcCHECK. The current correction factors were applied using both the new and current methods. The new method was also used to apply corrections to the original 19 ViewRay plans. It was found the ArcCHECK systematically reports doses higher than those actually delivered by the ViewRay. Application of the current correction factors by either method did not consistently improve measurement accuracy. As dose deposition and diode response have both been shown to change under the influence of a magnetic field, it can be concluded the current ArcCHECK correction factors are invalid and/or inadequate to correct measurements on the ViewRay system.
Asunto(s)
Imagen por Resonancia Magnética Intervencional/métodos , Neoplasias/radioterapia , Humanos , Imagen por Resonancia Magnética Intervencional/instrumentación , Neoplasias/diagnóstico por imagen , Fantasmas de Imagen , Garantía de la Calidad de Atención de Salud , Dosificación Radioterapéutica , Reproducibilidad de los ResultadosRESUMEN
INTRODUCTION: The gamma analysis used for quality assurance of a complex radiotherapy plan examines the dosimetric equivalence between planned and measured dose distributions within some tolerance. This study explores whether the dosimetric difference is correlated with any radiobiological difference between delivered and planned dose. METHODS: VMAT or IMRT plans optimized for 14 cancer patients were calculated and delivered to a QA device. Measured dose was compared against planned dose using 2-D gamma analysis. Dose volume histograms (for various patient structures) obtained by interpolating measured data were compared against the planned ones using a 3-D gamma analysis. Dose volume histograms were used in the Poisson model to calculate tumor control probability for the treatment targets and in the Sigmoid dose-response model to calculate normal tissue complication probability for the organs at risk. RESULTS: Differences in measured and planned dosimetric data for the patient plans passing at ≥94.9% rate at 3%/3 mm criteria are not statistically significant. Average ± standard deviation tumor control probabilities based on measured and planned data are 65.8±4.0% and 67.8±4.1% for head and neck, and 71.9±2.7% and 73.3±3.1% for lung plans, respectively. The differences in tumor control probabilities obtained from measured and planned dose are statistically insignificant. However, the differences in normal tissue complication probabilities for larynx, lungs-GTV, heart, and cord are statistically significant for the patient plans meeting ≥94.9% passing criterion at 3%/3 mm. CONCLUSION: A ≥90% gamma passing criterion at 3%/3 mm cannot assure the radiobiological equivalence between planned and delivered dose. These results agree with the published literature demonstrating the inadequacy of the criterion for dosimetric QA and suggest for a tighter tolerance.
Asunto(s)
Dosificación Radioterapéutica , Radioterapia de Intensidad Modulada/normas , Humanos , Distribución de Poisson , Radiobiología , Radiometría , Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada/métodosRESUMEN
AIM: The aim of this study is to evaluate performance of ArcCHECK diode array detector for the volumetric modulated arc therapy (VMAT) patient specific quality assurance (QA). VMAT patient specific QA results were correlated with ion chamber measurement. Dose response of the ArcCHECK detector was studied. BACKGROUND: VMAT delivery technique improves the dose distribution. It is complex in nature and requires proper QA before its clinical implementation. ArcCHECK is a novel three dimensional dosimetry system. MATERIALS AND METHODS: Twelve retrospective VMAT plans were calculated on ArcCHECK phantom. Point dose and dose map were measured simultaneously with ion chamber (IC-15) and ArcCHECK diode array detector, respectively. These measurements were compared with their respective TPS calculated values. RESULTS: The ion chamber measurements are in good agreement with TPS calculated doses. Mean difference between them is 0.50% with standard deviation of 0.51%. Concordance correlation coefficient (CCC) obtained for ion chamber measurements is 0.9996. These results demonstrate a strong correlation between the absolute dose predicted by our TPS and the measured dose. The CCC between ArcCHECK doses and TPS predictions on the CAX was found to be 0.9978. In gamma analysis of dose map, the mean passing rate was 98.53% for 3% dose difference and 3 mm distance to agreement. CONCLUSIONS: The VMAT patient specific QA with an ion chamber and ArcCHECK phantom are consistent with the TPS calculated dose. Statistically good agreement was observed between ArcCHECK measured and TPS calculated. Hence, it can be used for routine VMAT QA.
RESUMEN
A fundamental parameter to evaluate the beam delivery precision and stability on a clinical linear accelerator (linac) is the focal spot position (FSP) measured relative to the collimator axis of the radiation head. The aims of this work were to evaluate comprehensive data on FSP acquired on linacs in clinical use and to establish the ability of alternative phantoms to detect effects on patient plan delivery related to FSP. FSP measurements were conducted using a rigid phantom holding two ball-bearings at two different distances from the radiation source. Images of these ball-bearings were acquired using the electronic portal imaging device (EPID) integrated with each linac. Machine QA was assessed using a radiation head-mounted PTW STARCHECK phantom. Patient plan QA was investigated using the SNC ArcCHECK phantom positioned on the treatment couch, irradiated with VMAT plans across a complete 360° gantry rotation and three X-ray energies. This study covered eight Elekta linacs, including those with 6 MV, 18 MV, and 6 MV flattening-filter-free (FFF) beams. The largest range in the FSP was found for 6 MV FFF. The FSP of one linac, retrofitted with 6 MV FFF, displayed substantial differences in FSP compared to 6 MV FFF beams on other linacs, which all had FSP ranges less than 0.50 mm and 0.25 mm in the lateral and longitudinal directions, respectively. The PTW STARCHECK phantom proved effective in characterising the FSP, while the SNC ArcCHECK measurements could not discern FSP-related features. Minor variations in FSP may be attributed to adjustments in linac parameters, component replacements necessary for beam delivery, and the wear and tear of various linac components, including the magnetron and gun filament. Consideration should be given to the ability of any particular phantom to detect a subsequent impact on the accuracy of patient plan delivery.
RESUMEN
The objective of the study is to verify the dose delivered on helical tomotherapy based on treatment plan with varying virtual bolus (VB) thickness. The target was localized on the ArcCHECK image by 3 mm margin from the phantom surface. The dimension of target, which includes the ArcCHECK's detectors, with the 4.0 cm width and length 12.0 cm along the phantom The 5 treatment plans were generated, 1 plan without VB application (NoVB) and the 4 plans with varying of VB thickness on the phantom surface by 0.5 cm (VB0.5), 1.0 cm (VB1.0), 1.5 cm (VB1.5), and 2.0 cm (VB2.0), in treatment planning but absent during irradiation. For measurement analysis, the ionization chamber and the ArcCHECK detectors were used for point dose and dose distribution by investigating the percentage of dose difference and the gamma passing rate. The VB thickness 0.5, 1.0 and 1.5 cm showed acceptable value with less than 2% for dose difference by 0.37% (VB0.5), -0.11% (VB1.0) and -0.37% (VB1.5) at the center of ArcCHECK. The accuracy of dose distribution showed an acceptable gamma passing rate of 99.8% (VB0.5), 100% (VB1.0), and 90.2% (VB1.5) for gamma criteria by 3%/3mm for absolute dose analysis. However, the gamma passing rate of VB2.0 down to 71.2% of absolute mode for gamma criteria by 3%/3mm. The treatment plans with VB thickness less than 15 mm deliver doses that are comparable to treatment plans without virtual bolus based on gamma analysis. However, the deviation showed a trend increasing when VB thickness increased. The VB2.0 was not acceptable for point dose and dose distribution verification by more than 2% dose difference and less than 90% of gamma passing rate.
Asunto(s)
Radioterapia de Intensidad Modulada , Humanos , Radioterapia de Intensidad Modulada/métodos , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por Computador/métodos , Fantasmas de Imagen , Rayos gamma , Radiometría/métodosRESUMEN
There are several accepted methods to verify External Beam Radiation Therapy (EBRT) treatment plans, but there is no standard way to check the quality of a brachytherapy treatment plan. PURPOSE: This feasibility study assesses whether the ArcCHECK EBRT radiation detector can also be used to verify Treatment Planning System software quality check procedures for brachytherapy. METHODS AND MATERIALS: ArcCHECK is a three-dimensional matrix of 1386 semiconductor diodes, arranged spirally around an internal cylindrical space that is 32 cm long and 15 cm in diameter. The detector makes it possible to reproduce the distribution of sources in a planned EBRT procedure (energy range 6-22 MeV) using an appropriate phantom. Detector responses are displayed as a two-dimensional dose distribution map on the diode surface. In this pilot brachytherapy study, we determined values that characterized the output of the detectors to a simulated Ir-192 radiation source with an energy range of approximately 9-1378 keV, and compared this to the actual signal recorded by an ArcCHECK detector. Experimental treatment plan measurement was performed using a standard Elekta micro-Selectron-v2 unit equipped with an iridium-192 source. To avoid unit inconsistencies, the signal from each of the diodes and the simulation results were normalized to the maximum value, with similar statistical parameters. RESULTS: The difference between diode indications in the simulation and the actual measurement was analyzed statistically to show the degree of general inconsistency between them. The average difference for diode pairs here is equal 1,07%, with standard deviation 3, 95%. CONCLUSION: The results obtained represent the first quantitative evidence of potential usefulness of the ArcCHECK detector in brachytherapy Treatment Planning System software QC verification.